MarketCap
Facebook
X
Telegram
Accelerate Diagnostics Total Liabilities | AXDX
Annual Total Liabilities Accelerate Diagnostics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 84.6 M | 51.3 M | 87.3 M | 118 M | 156 M | 142 M | 128 M | 6.81 M | 5.04 M | 6.31 M | 3.81 M | 1.91 M | 2.38 M | 1.45 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 156 M | 1.45 M | 56.8 M |
Quarterly Total Liabilities Accelerate Diagnostics
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 80.8 M | 57.8 M | 56.5 M | 51.3 M | 74.4 M | 88.5 M | 89.7 M | 87.3 M | 85.8 M | 121 M | 126 M | 118 M | 121 M | 164 M | 159 M | 156 M | 154 M | 152 M | 143 M | 142 M | 137 M | 133 M | 129 M | 128 M | 123 M | 123 M | 107 M | 6.81 M | 6.18 M | 6.22 M | 5.27 M | 5.04 M | 5.45 M | 5.47 M | 5.99 M | 6.31 M | 4.57 M | 4 M | 4.52 M | 3.81 M | 2.88 M | 3.1 M | 2.61 M | 1.91 M | 939 K | 1.81 M | 1.14 M | 1.25 M | 1.66 M | 1.66 M | 1.59 M | 1.61 M | 1.59 M | 1.45 M | 1.45 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 164 M | 939 K | 58.3 M |
Total Liabilities of other stocks in the Diagnostics research industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Thermo Fisher Scientific
TMO
|
28.7 B | $ 694.85 | 2.62 % | $ 262 B |  USA |
 |
Akumin
AKU
|
1.62 B | - | -17.87 % | $ 25.9 M |  Canada |
 |
Trinity Biotech plc
TRIB
|
138 M | $ 6.07 | 2.97 % | $ 2.18 B |  Irlanda |
 |
Brainsway Ltd.
BWAY
|
14.4 M | $ 11.12 | 4.81 % | $ 378 M |  Israel |
 |
VolitionRx Limited
VNRX
|
42.5 M | $ 0.2 | 3.39 % | $ 25.2 M |  Singapore |
 |
Waters Corporation
WAT
|
2.52 B | $ 458.04 | 1.06 % | $ 27.3 B | USA |
 |
Exagen
XGN
|
40.6 M | $ 5.79 | -23.82 % | $ 125 M | USA |
 |
Guardant Health
GH
|
2.11 B | $ 151.28 | -1.4 % | $ 19 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
9.76 B | $ 366.98 | 1.02 % | $ 30.5 B | USA |
 |
IQVIA Holdings
IQV
|
23.3 B | $ 271.72 | 2.59 % | $ 46.7 B | USA |
 |
Quotient Limited
QTNT
|
338 M | - | -11.32 % | $ 1.1 M |  Schweiz |
 |
Chembio Diagnostics
CEMI
|
44.8 M | - | 0.22 % | $ 16.8 M | USA |
 |
DermTech
DMTK
|
64.8 M | - | -11.32 % | $ 2.94 M | USA |
 |
Surmodics
SRDX
|
59.7 M | - | - | $ 608 M | USA |
 |
Invitae Corporation
NVTA
|
1.85 B | - | - | $ 21.2 M | USA |
 |
Syneos Health
SYNH
|
4.7 B | - | - | $ 4.46 B | USA |
 |
Motus GI Holdings
MOTS
|
4.54 M | - | -34.28 % | $ 263 K | Israel |
 |
Heska Corporation
HSKA
|
164 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
12.4 M | - | -20.0 % | $ 1.06 M | USA |
 |
Renalytix AI plc
RNLX
|
15.8 M | - | 5.66 % | $ 22.7 M |  Britain |
 |
Psychemedics Corporation
PMD
|
3.19 M | - | -1.84 % | $ 15.3 M | USA |
 |
Meridian Bioscience
VIVO
|
135 M | - | - | $ 1.49 B | USA |
 |
Celcuity
CELC
|
366 M | $ 66.73 | 3.9 % | $ 3.12 B | USA |
 |
DexCom
DXCM
|
3.59 B | $ 79.42 | -5.97 % | $ 31 B | USA |
 |
Agilent Technologies
A
|
5.99 B | $ 175.14 | 1.97 % | $ 49.7 B | USA |
 |
Castle Biosciences
CSTL
|
108 M | $ 32.49 | -4.99 % | $ 942 M | USA |
 |
Anixa Biosciences
ANIX
|
2.13 M | $ 3.16 | 4.29 % | $ 103 K | USA |
|
Biodesix
BDSX
|
89.9 M | $ 8.51 | -57.13 % | $ 64.3 M | USA |
 |
BioNano Genomics
BNGO
|
29.2 M | $ 1.15 | 4.54 % | $ 6.26 M | USA |
 |
Bioventus
BVS
|
455 M | $ 10.61 | -0.66 % | $ 707 M | USA |
 |
Fulgent Genetics
FLGT
|
107 M | $ 23.68 | 26.9 % | $ 729 M | USA |
 |
CareDx, Inc
CDNA
|
110 M | $ 78.47 | 2.8 % | $ 4.18 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
21.6 M | - | - | $ 562 M | Britain |
 |
Biomerica
BMRA
|
4.13 M | $ 1.61 | -1.55 % | $ 4.69 M | USA |
 |
Interpace Biosciences
IDXG
|
11.5 M | $ 7.0 | -13.43 % | $ 31 M | USA |
 |
Fluidigm Corporation
FLDM
|
186 M | - | 1.08 % | $ 308 M | USA |
 |
ICON Public Limited Company
ICLR
|
7.08 B | $ 204.67 | 1.5 % | $ 16.1 B | Irlanda |
 |
Co-Diagnostics
CODX
|
4.11 M | $ 0.25 | -8.24 % | $ 333 K | USA |
 |
Burning Rock Biotech Limited
BNR
|
285 M | $ 13.2 | -0.38 % | $ 139 M |  China |
 |
PRA Health Sciences, Inc.
PRAH
|
2.7 B | - | - | $ 10.7 B | USA |
 |
DarioHealth Corp.
DRIO
|
7.26 M | $ 2.4 | -11.93 % | $ 9.56 M | Israel |
 |
Myriad Genetics
MYGN
|
339 M | $ 5.97 | -5.17 % | $ 553 M | USA |
 |
ENDRA Life Sciences
NDRA
|
1.59 M | $ 4.73 | -5.49 % | $ 3.72 M | USA |
 |
NeoGenomics
NEO
|
523 M | $ 16.85 | 2.18 % | $ 2.16 B | USA |
 |
OPKO Health
OPK
|
664 M | $ 1.72 | -1.71 % | $ 1.29 B | USA |
 |
Pacific Biosciences of California
PACB
|
779 M | $ 2.3 | -5.35 % | $ 690 M | USA |
 |
Neogen Corporation
NEOG
|
1.25 B | $ 11.75 | 0.6 % | $ 2.56 B | USA |
 |
Precipio
PRPO
|
6.76 M | $ 18.95 | 2.02 % | $ 30.4 M | USA |
 |
Personalis
PSNL
|
73 M | $ 15.76 | 1.32 % | $ 1.41 B | USA |
 |
Sotera Health Company
SHC
|
2.66 B | $ 16.01 | 0.88 % | $ 4.55 B | USA |